Cambridge Healthtech Institute’s 14th Annual
Portfolio Management
Aligning Portfolio and Productivity with Corporate Strategy to Drive Innovation and Value
October 17-18, 2019
In an environment of declining revenues and uncertain commercial success, biopharma, device and R&D companies need to continuously evaluate their portfolios. Manufacturers must make tough decisions about which products and projects to pursue to optimize
long-term revenue and reduce overall risk. Cambridge Healthtech Institute’s and the BioPharma Strategy Series’ 14th Annual Portfolio Management: Aligning Portfolio and Productivity with Corporate Strategy to Drive Innovation attracts
over 100 senior R&D executives from the pharma, biotech, device, IT, public and governmental communities who share best practices in project and portfolio management, R&D innovation, decision analysis, change management, forecasting, and the
improvement of operational models. Effective portfolio management requires the alignment of portfolio and productivity with corporate strategy, supporting agile development and adaptation of data into planning.
How to Develop an After-Action Review Culture – A Guide to Incremental BUT Impactful Change Management
Michael Myers, PhD, Senior Director, LRL Due Diligence, Eli Lilly & Co.
Analytics and Culture: Lessons Learned and Comparisons between Pharma/Biotech, Oil & Gas, and Government
Timothy Nieman, Senior Manager, Portfolio Analysis, Portfolio Management Office, BioMarin Pharmaceutical
Linking Corporate Strategic Portfolio to Projects through Governance
Matthew Kokkonen, Director, Portfolio Management and Governance, CSL Behring
Analyzing Governance Decision Making and the Impact of Team Preparedness
Christine Antis, Senior Director, Portfolio Governance and Head of Portfolio Decision Sciences, Portfolio Management, GlaxoSmithKline
Transformation Journey – Schedule Development & Execution
Gary Shives, Director, Project Management Office, Eli Lilly
Pragmatic Approach to Implementing Portfolio Management and Optimization
Crissy Tevis, Director, TOPS Portfolio Management, Technical Operations, BioMarin Pharmaceuticals
An Agile Approach to Portfolio Planning
Candy Liang, Director, Strategic Planning, Akebia Therapeutics
Building a Financial Model for Assets
Delfi Krishna, PhD, Director of Operations, Planning and Strategy, Cell and Gene Therapy Platform, GS
Validated Probability Assessments – Insights from Lilly’s 20 Years of Experience
Charles Persinger, Senior Research Advisor, Portfolio Strategy & Decision Sciences, Eli Lilly and Company
PANEL DISCUSSION: Simplifying Portfolio and Resource Management Processes in the Age of Analytics
Moderator: Daniel Patrick, Senior Director, Global Project Management and Leadership, Daiichi Sankyo
Panelists: Mark Lane, Executive Director of Drug Development, PRA Health Sciences
Raghu Sethuram, Senior Director, Global Portfolio Management, Pfizer Consumer Healthcare
For more details on the conference, please contact:
Kaitlin Searfoss Kelleher
Conference Producer
Cambridge Healthtech Institute
Phone: (+1) 781-972-5498
Email: kkelleher@healthtech.com
For partnering and sponsorship information, please contact:
Katelin Fitzgerald
Senior Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5458
Email: kfitzgerald@healthtech.com